Dr. Reddy’s Laboratories (Dr. Reddy’s Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to US-based Citius Pharmaceuticals in a deal worth up to $150 million. The Indian pharma company will get $40 million upfront upon the closing of the deal. It will be eligible […]
Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Previously, BNZ-1 was given orphan drug designation by the US Food and Drug Administration (FDA). Recently, Bioniz Therapeutics wrapped up a phase 2 study of BNZ-1 in […]
As per the Actelion recent news, the pharma’s Ledaga Chlormethine Gel 160 micrograms/g has been approved by the European Commission (EC) for CTCL MF treatment.
The European Commission (EC) has granted marketing authorization to Actelion Pharmaceuticals for its innovative Ledaga Chlormethine Gel 160 micrograms/g, designed for the treatment of cutaneous T-cell lymphoma of the mycosis fungoides-type (CTCL MF). This approval marks a significant advancement in the treatment options available for this rare and often life-threatening immune system cancer. Breakthrough in […]